Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Siponimod in Active Dermatomyositis
NCT02029274Phase 2Terminated
- Sponsor
- Novartis
- Start
- Aug 2013
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of siponimod in dermatomyositis (DM), sponsored by Novartis. Started Aug 2013; status: terminated.
02
Drugs
siponimod
03
Conditions
dermatomyositis (DM)
Beyond the preview
Go deeper on NCT02029274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02029274.